These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 6747440)

  • 1. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin.
    Wolf M; Boyer-Neumann C; Meyer D; Tripodi A; Mannucci PM; Larrieu MJ
    Thromb Haemost; 1987 Oct; 58(3):888-92. PubMed ID: 3433251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin III "Northwick Park": a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity.
    Howarth DJ; Samson D; Stirling Y; Seghatchian MJ
    Thromb Haemost; 1985 Jun; 53(3):314-9. PubMed ID: 4049307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.
    de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA
    Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin III Avranches, a new variant with defective serine-protease inhibition--comparison with antithrombin III Charleville.
    Aiach M; Roncato M; Chadeuf G; Dezellus P; Capron L; Fiessinger JN
    Thromb Haemost; 1988 Aug; 60(1):94-6. PubMed ID: 3187951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin.
    Clemmensen I
    Thromb Haemost; 1978 Jun; 39(3):616-23. PubMed ID: 705690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalities.
    De Stefano V; Leone G; Mastrangelo S; Lane DA; Girolami A; de Moerloose P; Sas G; Abildgaard U; Blajchman M; Rodeghiero F
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):7-15. PubMed ID: 8180341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous variant of antithrombin III: AT III Fontainebleau.
    Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ
    Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin-induced proteolysis of human antithrombin III: an outstanding contribution of heparin.
    Marciniak E
    Br J Haematol; 1981 Jun; 48(2):325-36. PubMed ID: 7236529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin.
    Lane DA; Flynn A; Ireland H; Erdjument H; Samson D; Howarth D; Thompson E
    Br J Haematol; 1987 Apr; 65(4):451-6. PubMed ID: 3580302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin III Alger: a new homozygous AT III variant.
    Fischer AM; Cornu P; Sternberg C; Mériane F; Dautzenberg MD; Chafa O; Beguin S; Desnos M
    Thromb Haemost; 1986 Apr; 55(2):218-21. PubMed ID: 3715788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial variant of antithrombin III (AT III Bligny, 47Arg to His) associated with protein C deficiency.
    Wolf M; Boyer-Neumann C; Molho-Sabatier P; Neumann C; Meyer D; Larrieu MJ
    Thromb Haemost; 1990 Apr; 63(2):215-9. PubMed ID: 2363123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification and properties of guinea pig antithrombin III.
    Heck L; Rosenberg R; Remold H
    Prep Biochem; 1979; 9(4):359-77. PubMed ID: 504072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin Glasgow, 393 Arg to His: a P1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity.
    Owen MC; Beresford CH; Carrell RW
    FEBS Lett; 1988 Apr; 231(2):317-20. PubMed ID: 3360140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of heparin binding to antithrombin III by crossed immunoelectrophoresis.
    Barrowcliffe TW
    Thromb Haemost; 1980 Feb; 42(5):1434-45. PubMed ID: 7368150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.